Percutaneous cryoablation of kidney tumors may be as effective as laparoscopy in eligible patients, according to research presented at the Society of Interventional Radiology’s 32nd annual scientific meeting in Seattle.
Percutaneous cryoablation of kidney tumors may be as effective as laparoscopy in eligible patients, according to research presented at the Society of Interventional Radiology’s 32nd annual scientific meeting in Seattle.
In a comparative trial, researchers found that percutaneous cryoablation yielded marginally lower tumor recurrence rates than laparoscopy (10.5% vs. 12.5%, respectively), reduced hospital stay (1.1 days vs. 2.5 days), minimal complications (0 vs. 6.3%), and substantially lower hospital costs (59.5% lower).
“This early-stage research indicates that percutaneous cryoablation in the appropriate patient population can effectively kill tumors, while also offering patients a shorter hospital stay, a faster recovery, and an excellent safety profile, all at a lower cost than laparoscopy,” said study author J. Louis Hinshaw, MD, of the University of Wisconsin. “Unfortunately, not all patients are viable candidates for percutaneous ablation, and we work closely with our urology colleagues to ensure that each patient receives the most appropriate treatment.”
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.